Azaribine

Azaribine
Clinical data
Trade namesTriazure
Legal status
Legal status
  • US: Withdrawn
Identifiers
  • [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(3,5-dioxo-1,2,4-triazin-2-yl)oxolan-2-yl]methyl acetate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.016.832 Edit this at Wikidata
Chemical and physical data
FormulaC14H17N3O9
Molar mass371.302 g·mol−1
3D model (JSmol)
  • CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C
  • InChI=1S/C14H17N3O9/c1-6(18)23-5-9-11(24-7(2)19)12(25-8(3)20)13(26-9)17-14(22)16-10(21)4-15-17/h4,9,11-13H,5H2,1-3H3,(H,16,21,22)/t9-,11-,12-,13-/m1/s1
  • Key:QQOBRRFOVWGIMD-OJAKKHQRSA-N

Azaribine (triacetyl-6-azauridine) is a drug developed by Calbiochem for the treatment of psoriasis, and also has anti-cancer and antiviral activities. It is a prodrug which is metabolised to the nucleoside analogue 6-azauridine in the body.

Azaribine received FDA approval in 1975 for the treatment of severe psoriasis, but was subsequently withdrawn from the market in 1976 (with its New Drug Application formally revoked in 1977), following reports of life-threatening thromboembolic events. These side effects, including both arterial and venous thrombosis, are primarily attributed to azaribine acting as a vitamin B6 antagonist, which induces a severe functional deficiency of pyridoxal phosphate and the resultant hyperhomocysteinemia. However, it continues to be researched as a potential agent for the treatment of emerging viral diseases.